Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

SAB Biotherapeutics (SABS) Leases (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Leases for 6 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Leases rose 168.28% year-over-year to $2.6 million, compared with a TTM value of $2.6 million through Dec 2025, up 168.28%, and an annual FY2025 reading of $2.6 million, up 168.28% over the prior year.
  • Leases was $2.6 million for Q4 2025 at SAB Biotherapeutics, down from $2.8 million in the prior quarter.
  • Across five years, Leases topped out at $4.0 million in Q4 2021 and bottomed at $493473.0 in Q3 2023.
  • Average Leases over 5 years is $2.3 million, with a median of $2.4 million recorded in 2022.
  • The sharpest move saw Leases crashed 87.42% in 2023, then surged 229.72% in 2025.
  • Year by year, Leases stood at $4.0 million in 2021, then tumbled by 70.34% to $1.2 million in 2022, then surged by 207.84% to $3.7 million in 2023, then plummeted by 73.56% to $970294.0 in 2024, then skyrocketed by 168.28% to $2.6 million in 2025.
  • Business Quant data shows Leases for SABS at $2.6 million in Q4 2025, $2.8 million in Q3 2025, and $3.0 million in Q2 2025.